{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:03:19Z","timestamp":1785402199391,"version":"3.56.0"},"reference-count":29,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Scientific Research Projects Commission of Karamano\u011flu Mehmetbey University","award":["41-M-24"],"award-info":[{"award-number":["41-M-24"]}]},{"award":["41-M-24"],"award-info":[{"award-number":["41-M-24"]}],"id":[{"id":"https:\/\/ror.org\/037vvf096","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Triple-negative breast cancer (TNBC) is characterized by aggressive clinical behavior and limited targeted therapeutic options. Hypoxia signaling mediated by hypoxia-inducible factor-1\u03b1 (HIF-1\u03b1) and mitochondrial antioxidant defense driven by superoxide dismutase 2 (SOD2) represent biologically interconnected stress-adaptation pathways that may contribute to tumor progression. However, their combined prognostic impact in TNBC remains insufficiently defined. This retrospective study included 70 patients with surgically treated TNBC. Immunohistochemical expression of HIF-1\u03b1 (nuclear) and SOD2 (cytoplasmic) was semi-quantitatively scored and analyzed individually and in combination. Patients were stratified as both-low, single-high, or both-high expression. Associations with clinicopathological parameters were evaluated, and overall survival (OS) and disease-free survival (DFS) were analyzed using Kaplan\u2013Meier and Cox regression models. Stage-adjusted and stage-free multivariable analyses were performed, and sensitivity analyses using penalized Cox regression were conducted. High SOD2 expression was observed in 68.6% and high HIF-1\u03b1 expression in 24.3% of cases. Neither marker was independently associated with survival outcomes in Kaplan\u2013Meier or multivariable analyses. HIF-1\u03b1-high tumors showed a nominally lower Ki-67 proliferation index compared with HIF-1\u03b1-low tumors (median 30.0% vs. 60.0%, p = 0.023); however, given the number of comparisons performed, this finding should be regarded as exploratory and interpreted cautiously. Advanced stage and distant metastasis were the strongest predictors of both OS and DFS. In post hoc exploratory analyses, increasing SOD2 (HR 1.36 per point, p = 0.039) and HIF-1\u03b1 scores (HR 1.80 per point, p = 0.022) showed nominal associations with worse OS; these findings are hypothesis-generating and should not be interpreted as evidence of independent prognostic value. Combined biomarker stratification showed a numerical stepwise pattern of OS curves, with the poorest survival observed in the both-high group, although statistical significance was not reached. High SOD2 expression is frequent in TNBC and may reflect underlying tumor biology; however, this was not independently confirmed in survival analyses. Continuous biomarker scoring suggests an incremental association with overall survival. Combined HIF-1\u03b1\/SOD2 assessment did not demonstrate independent prognostic value in this cohort. These observations are hypothesis-generating and require validation in larger, prospectively designed cohorts before any clinical application can be considered.<\/jats:p>","DOI":"10.3390\/ijms27125343","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:57:58Z","timestamp":1781513878000},"page":"5343","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated Assessment of HIF-1\u03b1 and SOD2 Expression and Their Prognostic Implications in Triple-Negative Breast Cancer"],"prefix":"10.3390","volume":"27","author":[{"given":"Burcu Sanal","family":"Y\u0131lmaz","sequence":"first","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Karamano\u011flu Mehmetbey University, Karaman 70200, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezer Seda","family":"Y\u0131lmaz","sequence":"additional","affiliation":[{"name":"Van Branch of the Council of Forensic Medicine, Van 65080, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3220-7845","authenticated-orcid":false,"given":"Zeliha Esin","family":"\u00c7elik","sequence":"additional","affiliation":[{"name":"Department of Pathology, Faculty of Medicine, Selcuk University, Konya 42130, Turkey"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: Challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12609-023-00492-4","article-title":"Exploiting therapeutic vulnerabilities in triple-negative breast cancer: Successes, challenges, and opportunities","volume":"15","author":"Matossian","year":"2023","journal-title":"Curr. Breast Cancer Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1631\/jzus.B1400221","article-title":"Hypoxia-inducible factor 1 and breast cancer metastasis","volume":"16","author":"Liu","year":"2015","journal-title":"J. Zhejiang Univ. Sci. B"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"R191","DOI":"10.1186\/bcr775","article-title":"Hypoxia-inducible factor 1 alpha in high-risk breast cancer: An independent prognostic parameter?","volume":"6","author":"Gruber","year":"2004","journal-title":"Breast Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"113922","DOI":"10.1016\/j.bcp.2020.113922","article-title":"HIF-1 stabilization exerts anticancer effects in breast cancer cells in vitro and in vivo","volume":"175","author":"Podkalicka","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2174\/1566524018666181109121849","article-title":"Role of HIF-1 in cancer progression: Novel insights","volume":"18","author":"Pezzuto","year":"2018","journal-title":"Curr. Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"S62","DOI":"10.1016\/S1471-4914(02)02317-1","article-title":"HIF-1 and tumor progression: Pathophysiology and therapeutics","volume":"8","author":"Semenza","year":"2002","journal-title":"Trends Mol. Med."},{"key":"ref_8","first-page":"602","article-title":"Manganese superoxide dismutase (MnSOD) genetic polymorphisms, dietary antioxidants, and risk of breast cancer","volume":"59","author":"Ambrosone","year":"1999","journal-title":"Cancer Res."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"23534","DOI":"10.1073\/pnas.1902308116","article-title":"SOD2 acetylation on lysine 68 promotes stem cell reprogramming in breast cancer","volume":"116","author":"He","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/s10549-007-9597-5","article-title":"Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells","volume":"108","author":"Kattan","year":"2008","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s10549-025-07775-7","article-title":"SOD2 expression in patients with triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and prognosis","volume":"213","author":"Kim","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1158\/1055-9965.EPI-07-0160","article-title":"Functional variant of manganese superoxide dismutase (SOD2 V16A) polymorphism is associated with prostate cancer risk in the prostate, lung, colorectal, and ovarian cancer study","volume":"16","author":"Kang","year":"2007","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"5412","DOI":"10.1074\/jbc.C113.526475","article-title":"SOD2 to SOD1 switch in breast cancer","volume":"289","author":"Papa","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"579","DOI":"10.3892\/mco.2017.1376","article-title":"There is no relationship between SOD2 Val-16Ala polymorphism and breast cancer risk or survival","volume":"7","author":"Wang","year":"2017","journal-title":"Mol. Clin. Oncol."},{"key":"ref_15","first-page":"1103","article-title":"Expression of superoxide dismutase 2 in breast cancer and its clinical significance","volume":"40","author":"Li","year":"2020","journal-title":"J. South Med. Univ."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1186\/1476-4598-9-191","article-title":"Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia","volume":"9","author":"Flamant","year":"2010","journal-title":"Mol. Cancer"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"16369","DOI":"10.1073\/pnas.1113483108","article-title":"Hypoxia-inducible factor 1 is a master regulator of breast cancer metastatic niche formation","volume":"108","author":"Wong","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s10549-009-0725-2","article-title":"No association between SOD2 Val16Ala polymorphism and breast cancer susceptibility: A meta-analysis","volume":"122","author":"Ma","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"E6215","DOI":"10.1073\/pnas.1520032112","article-title":"HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells","volume":"112","author":"Zhang","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1093\/annonc\/mdy024","article-title":"Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis","volume":"29","author":"Bareche","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s12276-024-01180-8","article-title":"Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer","volume":"56","author":"Bae","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bigos, K.J.A., Quiles, C.G., Lunj, S., Smith, D.J., Krause, M., Troost, E.G., West, C.M., Hoskin, P., and Choudhury, A. (2024). Tumour response to hypoxia: Understanding the hypoxic tumour microenvironment to improve treatment outcome in solid tumours. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1331355"},{"key":"ref_23","first-page":"e70700","article-title":"Hypoxia-inducible factor 1-alpha (HIF-1\u03b1) and cancer: Mechanisms of tumor hypoxia and therapeutic targeting","volume":"16","author":"Basheeruddin","year":"2024","journal-title":"Cureus"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41419-021-04486-x","article-title":"Targeting prooxidant MnSOD effect inhibits triple-negative breast cancer (TNBC) progression and M2 macrophage functions under the oncogenic stress","volume":"13","author":"Tseng","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Juliachs, M., Pujals, M., Bellio, C., Meo-Evoli, N., Duran, J.M., Zamora, E., Par\u00e9s, M., Su\u00f1ol, A., M\u00e9ndez, O., and S\u00e1nchez-Pla, A. (2022). Circulating SOD2 is a candidate response biomarker for neoadjuvant therapy in breast cancer. Cancers, 14.","DOI":"10.3390\/cancers14163858"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/s41418-022-00963-8","article-title":"A novel HIF-2\u03b1 targeted inhibitor suppresses hypoxia-induced breast cancer stemness via SOD2-mtROS-PDI\/GRP78-UPRER axis","volume":"29","author":"Yan","year":"2022","journal-title":"Cell Death Differ."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Qannita, R.A., Alalami, A.I., Harb, A.A., Aleidi, S.M., Taneera, J., Abu-Gharbieh, E., El-Huneidi, W., Saleh, M.A., Alzoubi, K.H., and Semreen, M.H. (2024). Targeting hypoxia-inducible factor-1 (HIF-1) in cancer: Emerging therapeutic strategies and pathway regulation. Pharmaceuticals, 17.","DOI":"10.3390\/ph17020195"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/j.1582-4934.2009.00944.x","article-title":"Assessment of tumour hypoxia for prediction of response to therapy and cancer prognosis","volume":"14","author":"Jubb","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Alateyah, N., Gupta, I., Rusyniak, R.S., and Ouhtit, A. (2022). SOD2, a potential transcriptional target underpinning CD44-promoted breast cancer progression. Molecules, 27.","DOI":"10.3390\/molecules27030811"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5343\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T09:08:29Z","timestamp":1781514509000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":29,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27125343"],"URL":"https:\/\/doi.org\/10.3390\/ijms27125343","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]}}}